Penelope Drake, Ph.D., head of R&D, Bioconjugates, Catalent, highlights the potential of antibody-drug conjugates in paving a way to innovation in oncology treatments.
Shutterstock
Next-generation ADCs: better oncology treatments through innovation
Penelope Drake, Ph.D., head of R&D, Bioconjugates, Catalent, highlights the potential of anti-body-drug conjugates in paving a way to innovation in oncology treatments.
Published:
|
4 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.